Avelumab plus axitinib (A plus Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial

被引：0
|
作者：
Oya, M. [1 ]
Motzer, R. J. [2 ]
Choueiri, T. K. [3 ]
Haanen, J. B. A. G. [4 ]
Eto, M. [5 ]
Uemura, H. [6 ]
Venugopal, B. [7 ]
Rini, B. I. [8 ]
Miyake, H. [9 ]
Albiges, L. [10 ]
Schmidinger, M. [11 ]
Tomita, Y. [12 ,13 ]
Umeyama, Y. [14 ]
Ellers-Lenz, B. [15 ]
Hoffman, J. [16 ]
Larkin, J. [17 ]
机构：
[1] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[4] Netherlands Canc Inst, Amsterdam, Netherlands
[5] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan
[6] Kindai Univ, Fac Med, Dept Urol, Osakasayama, Japan
[7] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[8] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[9] Kobe Univ, Grad Sch Med, Div Urol, Kobe, Hyogo, Japan
[10] Inst Gustave Roussy, Villejuif, France
[11] Med Univ Vienna, Vienna, Austria
[12] Niigata Univ, Grad Sch Med, Dept Urol, Niigata, Japan
[13] Niigata Univ, Grad Sch Med, Dept Mol Oncol, Niigata, Japan
[14] Pfizer Japan Inc, Clin & Res Dept, Oncol, Shibuya Ku, Tokyo, Japan
[15] Merck Healthcare KGaA, Darmstadt, Germany
[16] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[17] Royal Marsden Hosp, London, England
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
292P
引用
收藏
页码：S1517 / S1518
页数：2
相关论文
共 50 条
  • [1] Efficacy of avelumab plus axitinib (A plus Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial
    Eto, M.
    Motzer, R. J.
    Choueiri, T. K.
    Haanen, J. B. A. G.
    Oya, M.
    Uemura, H.
    Venugopal, B.
    Rini, B. I.
    Miyake, H.
    Albiges, L.
    Schmidinger, M.
    Tomita, Y.
    Umeyama, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1512 - S1513
  • [2] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Campbell, Matthew T.
    Alekseev, Boris Y.
    Uemura, Motohide
    Kollmannsberger, Christian K.
    Gravis, Gwenaelle
    Bjarnason, Georg A.
    Gurney, Howard
    Chung, Jinsoo
    Haanen, John B. A. G.
    Rini, Brian I.
    Larkin, James M. G.
    Schmidinger, Manuela
    Nole, Franco
    Chudnovsky, Aleksander
    Huang, Bo
    Hariharan, Subramanian
    di Pietro, Alessandra
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Albiges, Laurence
    Haanen, John B. A. G.
    Larkin, James M. G.
    Uemura, Motohide
    Pal, Sumanta K.
    Gravis, Gwenaelle
    Campbell, Matthew T.
    Penkov, Konstantin
    Lee, Jae-Lyun
    Ching, Keith A.
    Mu, Xinmeng Jasmine
    Wang, Xiao
    Zhang, Weidong
    Wang, Jing
    Chudnovsky, Aleksander
    di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
    Motzer, Robert J.
    Penkov, Konstantin
    Uemura, Hirotsugu
    Campbell, Matthew T.
    Kollmannsberger, Christian K.
    Lee, Jae-Lyun
    Venugopal, Balaji
    Van Den Eertwegh, Alfonsus
    Negrier, Sylvie
    Gurney, Howard
    Albiges, Laurence
    Berger, Raanan
    Haanen, John
    Rini, Brian I.
    Larkin, James
    Schmidinger, Manuela
    Sandner, Robin
    Wang, Jing
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Donahue, Amber C.
    Rini, Brian I.
    Powles, Thomas
    Haanen, John B. A. G.
    Larkin, James
    Mu, Xinmeng Jasmine
    Pu, Jie
    Thomaidou, Despina
    Di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S)
    Choueiri, T. K.
    Larkin, J. M. G.
    Pal, S. K.
    Motzer, R. J.
    Venugopal, B.
    Alekseev, B. Y.
    Miyake, H.
    Gravis, G.
    Bilen, M. A.
    Chudnovsky, A.
    Ching, K. A.
    Mariani, M.
    Robbins, P. B.
    Huang, B.
    di Pietro, A.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 361 - 361
  • [7] Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
    Uemura, Motohide
    Tomita, Yoshihiko
    Miyake, Hideaki
    Hatakeyama, Shingo
    Kanayama, Hiro-omi
    Numakura, Kazuyuki
    Takagi, Toshio
    Kato, Tomoyuki
    Eto, Masatoshi
    Obara, Wataru
    Uemura, Hirotsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Fujii, Yosuke
    Kamei, Yoichi
    Umeyama, Yoshiko
    Di Pietro, Alessandra
    Oya, Mototsugu
    CANCER SCIENCE, 2020, 111 (03) : 907 - 923
  • [8] Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
    Albiges, L.
    Rini, B. I.
    Haanen, J. B. A. G.
    Motzer, R. J.
    Kollmannsberger, C. K.
    Negrier, S.
    Nole, F.
    Bedke, J.
    Bilen, M. A.
    Nathan, P.
    Tomita, Y.
    Huang, B.
    Ching, K. A.
    Chudnovsky, A.
    Robbins, P. B.
    di Pietro, A.
    Thomaidou, D.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] JAVELIN renal 101: A randomized, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Penkov, K.
    Haanen, J. B. A. G.
    Rini, B. I.
    Albiges, L.
    Campbell, M. T.
    Kollmannsberger, C. K.
    Negrier, S.
    Uemura, M.
    Lee, J. L.
    Gurney, H.
    Berger, R.
    Schmidinger, M.
    Larkin, J.
    Atkins, M. B.
    Wang, J.
    Robbins, P. B.
    Chudnovsky, A.
    Di Pietro, A.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 724 - 724
  • [10] Randomized phase III trial of avelumab plus axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
    Uemura, M.
    Tomita, Y.
    Miyake, H.
    Hatakeyama, S.
    Kanayama, H-O.
    Numakura, K.
    Takagi, T.
    Kato, T.
    Eto, M.
    Obara, W.
    Uemura, H.
    Motzer, R. J.
    Fujii, Y.
    Kamei, Y.
    Oya, M.
    ANNALS OF ONCOLOGY, 2019, 30
12345